5/3
08:00 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $65.00 to $76.00. They now have a "sell" rating on the stock.
Neutral
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $65.00 to $76.00. They now have a "sell" rating on the stock.
5/3
05:12 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JMP Securities from $114.00 to $125.00. They now have a "market outperform" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JMP Securities from $114.00 to $125.00. They now have a "market outperform" rating on the stock.
5/3
05:06 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at HC Wainwright from $125.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at HC Wainwright from $125.00 to $135.00. They now have a "buy" rating on the stock.
5/3
11:53 am
bpmc
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises [Yahoo! Finance]
Low
Report
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises [Yahoo! Finance]
5/3
11:24 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $70.00 to $75.00. They now have an "equal weight" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $70.00 to $75.00. They now have an "equal weight" rating on the stock.
5/3
10:16 am
bpmc
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
09:57 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Piper Sandler from $78.00 to $104.00. They now have a "neutral" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Piper Sandler from $78.00 to $104.00. They now have a "neutral" rating on the stock.
5/2
04:13 pm
bpmc
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors [Yahoo! Finance]
Low
Report
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors [Yahoo! Finance]
5/2
08:10 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
5/2
07:21 am
bpmc
Blueprint Medicines: Q1 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Blueprint Medicines: Q1 Earnings Snapshot [Yahoo! Finance]
5/2
07:13 am
bpmc
Blueprint Medicines GAAP EPS of $1.40 beats by $3.05, revenue of $96.12M beats by $14.68M [Seeking Alpha]
Low
Report
Blueprint Medicines GAAP EPS of $1.40 beats by $3.05, revenue of $96.12M beats by $14.68M [Seeking Alpha]
5/2
07:13 am
bpmc
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance [Yahoo! Finance]
Medium
Report
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance [Yahoo! Finance]
5/2
07:00 am
bpmc
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
High
Report
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
5/2
04:22 am
bpmc
Project Optimus: helping or hindering cancer drug development? [Yahoo! Finance]
High
Report
Project Optimus: helping or hindering cancer drug development? [Yahoo! Finance]
4/26
12:00 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Stifel Nicolaus from $120.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Stifel Nicolaus from $120.00 to $130.00. They now have a "buy" rating on the stock.
4/26
11:13 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $110.00 price target on the stock.
4/26
08:11 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
4/26
08:11 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $125.00 price target on the stock.
4/25
11:44 am
bpmc
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]
Low
Report
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]
4/18
08:00 am
bpmc
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Low
Report
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
4/11
08:14 am
bpmc
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]
Low
Report
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]
4/11
08:00 am
bpmc
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Medium
Report
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
4/10
11:20 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
4/4
04:01 pm
bpmc
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/29
07:34 am
bpmc
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? [Yahoo! Finance]